A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (ARMOR2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Tokai Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Tokai Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01709734
First received: October 16, 2012
Last updated: May 23, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)